Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – Asia,
Asia: Japan
Japanese health products company seeks to sell 90% equity
The Japanese company is mainly engaged in the original equipment manufacturer ("OEM") production of health food, medicines, quasi medicines, cosmetics and other products, among which health food accounts for 75%. The company has 700 employees. In 2019, the company's revenue is USD 165.36 million (JPY 21.2 billion), earnings before interest ("EBITDA") is USD 2.5 million (JPY 320 million), and net profit is USD 8.58 million (JPY 110 million). The company seeks to sell 90% equity.
Asia: Singapore
Singaporean trading company seeks 60% controlling interest transfer
The Singaporean company's main products include polyethylene, polypropylene, etc. It is a listed company which has 109 employees. The company's price earnings ratio (P/E) is 23.61. Its net asset value is USD 46.8 million (SGD 64.64 million). The company seeks to transfer 60% controlling interest.
Asia: Japan
Japanese transformer and electromagnetic coil company seeks USD 3.1 million capital increase and USD 780k shares transfer
One product of the company is water cooled transformers. The company also has developed patented electromagnetic forming technology and mainly used it to make motor vehicles, especially new energy vehicles. Compared with ordinary transformers, the Japanese company's electromagnets can make the coil area very small. Therefore, the length of the magnetic circuit is shortened, and the magnetic circuit (iron core) can be made smaller and lighter. The company provides important parts for Hitachi's heavy ion medical equipment. In March 2020, the company's sales are USD 6.24 million (JPY 800 million). The company seeks to increase its capital of USD 3.1 million (JPY 400 million) and transfer USD 780K (JPY 100 million) old shares, of which controlling stake can be sold.
Asia: South Korea
Korean bonding tool company seeks investment
The Korean company's main products are high-precision micro bonding tools. Its capillary material products have the advantages of low cost, long service life and friendly parameter setting of welding machine. The company has more than 100 employees. There are factories in Korea and Vietnam. The company has representative offices in China, Japan, the Philippines and the United States. Through agents, the company has more than 100 customers worldwide. Now it seeks investment.
Asia: South Korea
Korean cutting equipment company seeks investment
The company's main products are metal bond cutting blades, resin bond cutting blades, combined cutting blades, electroforming cutting blades, etc. Its cutting tools can be applied on many materials such as high-temperature co-fired ceramics ("HTCC"). The company's sales in 2017 is USD 3.27 million. The main customers are Samsung, LG, etc. Now the company seeks investment.
Asia: Japan
Japanese biopharmaceutical start-up seeks about USD 10 million B-round financing
The Japanese company develops DNA and RNA editing technology in the field of innovative medicines and chemical medicines, whose intellectual property assets may be granted rights to others under a licence, sublicence or other contract. The company's core is RNA-PPR technology. Its current products include repetitive motif RNA control platform, RNA splicing control platform and protein translation activation platform. The company seeks about USD 10 million (JPY 13 billion) B-round financing.
Asia: Japan
Japanese hydrogen fuel cell company seeks JV partners in China
The Japanese company produces hydrogen fuel cells with platinum-free catalysts. The technology is patented. The company's hydrogen fuel cell has the advantages of lighter weight, lower cost and more power generation. Even after 6,000 cycles (12 times the conventional cycle), the power generation capacity remains high. The company seeks JV partners in China on royalty payment base for technology transfer priced at USD 12 million.
Asia: South Korea
Korean chemical company seeks USD 4 million working capital
The Korean company owns the key technologies of polyimide manufacturing such as polymers, composite material synthesis, etc. Its current shareholder structure is as the followings: founding team (CEO, COO, CTO) holds 29.3%, institutional investment (i.e. Samsung Venture) stands for 55.5%, and the rest are 15.2%. In 2023, the company's sales are expected to reach USD 25 million (KRW 31.1 billion) with profits of USD 6.4 million (KRW 8 billion). The company has completed its USD 4.8 million (KRW 6 billion) B-round financing. Now the company seeks USD 4 million (KRW 5 billion) for the working capital of its second factory.
Asia: Singapore
Singaporean smart controller company seeks strategic investor to be listed on China's Growth Enterprise Market
The Singaporean listed company mainly engages in the production and sales of smart controllers. Its main production bases are in Malaysia and China and main customers are based in Europe. The company's annual sales revenue is USD 63-79 million while net profit is USD 1-1.25 million. Its net cash is over USD 36 million. Over the past 5 years, the company has over USD 21.63 million in dividends. The company seeks a Chinese strategic investor to be listed on China's Growth Enterprise Market in the next 3 years.
Asia: Japan
Japanese food company seeks 100% equity investor
The Japanese company's products are cheese and other dairy products. The company owns a complete production line and supporting equipment. Two new production lines can be added to its factory and there is space left for new factories. The company has earned USD 890 thousand reveune in 2019. Now it seeks 100% equity.
Asia: South Korea
Korean stem cell therapy company seeks USD 20 million B-round financing
The Korean company provides three types of stem cell therapies. First, its Natural Killer ("NK") immune cell therapy is used for treatment of prostate cancer, ovarian cancer and lung cancer. Second, its mesenchymal stem cell ("MSC") therapy is used for treatment of degenerative arthrits of the knee. Third, its TSC differentiated cell induction technology is used for treatment of Charcot-Marie-Tooth disease. All of these have completed Phase I clinical trials in 2021. The company is a leader in the industry of immune cell therapy but also in the industry of second-generation cytogenetic therapy. Its current value is about USD 80 million. The company seeks USD 20 million B-round financing.
Asia: South Korea
Korean OLED lighting company seeks JV partners in China
The Korean company manufactures Organic Light Emitting Diodes ("OLED") high-end commercial lighting. Its original manufacturing process reduces the cost to one-tenth of that of competitors in the same industry. Now the company seeks to set up a joint venture in China with an estimated investment of USD 32 million.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us